Flamel Technologies S.A. (NASDAQ:AVDL) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $0.30-0.45 for the period, compared to the Thomson Reuters consensus estimate of $0.35. The company issued revenue guidance of $165-175 million, compared to the consensus revenue estimate of $177.31 million.

Shares of Flamel Technologies S.A. (AVDL) opened at 9.23 on Tuesday. The stock’s market cap is $381.90 million. Flamel Technologies S.A. has a 1-year low of $8.75 and a 1-year high of $15.45. The stock’s 50 day moving average is $10.49 and its 200-day moving average is $10.03.

Flamel Technologies (NASDAQ:AVDL) last announced its quarterly earnings results on Tuesday, May 9th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.19. The business had revenue of $52.50 million during the quarter, compared to the consensus estimate of $46.01 million. Flamel Technologies had a negative net margin of 7.28% and a positive return on equity of 14.49%. The business’s quarterly revenue was up 45.0% compared to the same quarter last year. On average, analysts predict that Flamel Technologies S.A. will post $0.54 EPS for the current fiscal year.

Separately, Zacks Investment Research upgraded shares of Flamel Technologies from a hold rating to a buy rating and set a $12.00 price target for the company in a report on Monday, July 17th.

In related news, Director Craig R. Stapleton purchased 31,013 shares of the business’s stock in a transaction dated Monday, May 22nd. The stock was acquired at an average price of $9.85 per share, for a total transaction of $305,478.05. Following the acquisition, the director now directly owns 507,678 shares of the company’s stock, valued at approximately $5,000,628.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Healthcare Master Fun Broadfin sold 261,000 shares of the stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $10.68, for a total transaction of $2,787,480.00. The disclosure for this sale can be found here. Company insiders own 5.07% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/08/flamel-technologies-s-a-avdl-releases-fy17-earnings-guidance.html.

About Flamel Technologies

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.

Earnings History and Estimates for Flamel Technologies (NASDAQ:AVDL)

Receive News & Ratings for Flamel Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.